Treatment Advances in Gastrointestinal Stromal Tumor With Shreyaskumar Patel, MD is organized by i3 Health.

Release: July 10, 2020
Expiration: July 9, 2021

Accreditation:
Physicians
i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. 

Nursing Continuing Professional Development
A maximum of 0.25 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses. 

Overview:
The fact that gastrointestinal stromal tumor (GIST) is a rare tumor type, with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest therapeutic developments. Treatment for GIST has seen exciting progress this year, with two new FDA approvals for metastatic disease. This episode of Oncology Data Advisor features Dr. Shreyaskumar Patel, Robert R. Herring Distinguished Professor of Cancer Research and Center Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center in Houston, Texas, in a discussion that covers the changing treatment landscape, adverse events of concern with novel therapies, and advice for members of the cancer care team as they seek to optimize outcomes for patients with GIST.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Evaluate emerging data on later-line treatment selection for individual patients with GIST
• Apply strategies to manage adverse events related to novel GIST treatments
Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.